137 related articles for article (PubMed ID: 18851896)
1. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen.
Argov M; Kashi R; Peer D; Margalit R
Cancer Lett; 2009 Feb; 274(1):118-25. PubMed ID: 18851896
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
4. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Schneiderman RS; Shmueli E; Kirson ED; Palti Y
BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
[TBL] [Abstract][Full Text] [Related]
5. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
7. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.
Gao Q; Li XX; Xu YM; Zhang JZ; Rong SD; Qin YQ; Fang J
Cancer Lett; 2020 Apr; 476():67-74. PubMed ID: 32061752
[TBL] [Abstract][Full Text] [Related]
8. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo.
Stein U; Walther W; Lemm M; Naundorf H; Fichtner I
Int J Cancer; 1997 Sep; 72(5):885-91. PubMed ID: 9311609
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
11. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
12. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein.
Zhang FY; Du GJ; Zhang L; Zhang CL; Lu WL; Liang W
Pharm Res; 2009 Apr; 26(4):914-25. PubMed ID: 19067124
[TBL] [Abstract][Full Text] [Related]
13. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
16. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
[TBL] [Abstract][Full Text] [Related]
18. Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.
Chen Y; Scully M; Petralia G; Kakkar A
Cancer Biol Ther; 2014 Jan; 15(1):135-45. PubMed ID: 24253450
[TBL] [Abstract][Full Text] [Related]
19. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
20. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
